Literature DB >> 27865278

Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer.

Stephanie M Kim1, Jennifer R Eads2.   

Abstract

Pancreatic adenocarcinoma is a relatively uncommon malignancy associated with a high rate of cancer-related mortality despite best efforts to perform curative surgery. Adjuvant therapy in patients after surgical resection is associated with improved overall survival. Adjuvant treatment approaches may include either chemotherapy alone or a combination of chemotherapy and radiation therapy. Neoadjuvant approaches, also including either chemotherapy alone or a combination of chemotherapy and radiation therapy, are under investigation. Periampullary cancers constitute a rare and heterogeneous group of tumors that are typically treated as pancreatic cancers given their histologic similarities and tumor location.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant; Neoadjuvant; Pancreatic adenocarcinoma; Pancreatic cancer; Periampullary cancer

Mesh:

Year:  2016        PMID: 27865278     DOI: 10.1016/j.suc.2016.07.004

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   3.537


  7 in total

Review 1.  Pancreaticoduodenectomy with Replaced Common Hepatic Artery and Portal Vein Reconstruction in Primary Carcinoma Duodenum: a Case Report and Literature Review.

Authors:  Gunjan S Desai; Prasad Pande; Rajiv C Shah; Palepu Jagannath
Journal:  J Gastrointest Cancer       Date:  2019-09

Review 2.  Adjuvant therapy for periampullary carcinoma and the significance of histopathological typing: A systematic review.

Authors:  Zhiqing Duan; Yinuo Zhang; Yajie Tang; Ruqing Gao; Jing Bao; Bo Liang
Journal:  Transl Oncol       Date:  2022-04-06       Impact factor: 4.243

Review 3.  Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.

Authors:  Guido Giordano; Massimo Pancione; Nunzio Olivieri; Pietro Parcesepe; Marianna Velocci; Tania Di Raimo; Luigi Coppola; Giuseppe Toffoli; Mario Rosario D'Andrea
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

Review 4.  Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer.

Authors:  Manju D Chandrasegaram; Anthony J Gill; Jas Samra; Tim Price; John Chen; Jonathan Fawcett; Neil D Merrett
Journal:  World J Gastrointest Oncol       Date:  2017-10-15

5.  Apparent diffusion coefficient-based histogram analysis differentiates histological subtypes of periampullary adenocarcinoma.

Authors:  Jing-Yu Lu; Hao Yu; Xian-Lun Zou; Zhen Li; Xue-Mei Hu; Ya-Qi Shen; Dao-Yu Hu
Journal:  World J Gastroenterol       Date:  2019-10-28       Impact factor: 5.742

6.  A CT-Based Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Periampullary Carcinomas.

Authors:  Lei Bi; Yubo Liu; Jingxu Xu; Ximing Wang; Tong Zhang; Kaiguo Li; Mingguang Duan; Chencui Huang; Xiangjiao Meng; Zhaoqin Huang
Journal:  Front Oncol       Date:  2021-07-29       Impact factor: 6.244

7.  Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Hye Jin Kim; Mi-Suk Park; Jin Yong Lee; Kyunghwa Han; Yong Eun Chung; Jin-Young Choi; Myeong-Jin Kim; Chang Moo Kang
Journal:  Cancer Res Treat       Date:  2018-02-05       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.